Categories: Washington Post

2 9/19/2018

One woman’s account of spinal cord stimulator skips realities of medical device safety in U.S.

6/27/2018

FDA approves new marijuana-derived drug, but was the evidence solid? Washington Post doesn’t say

4/17/2018

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

1/31/2018

Washington Post story on hyperbaric therapy for head injuries notes uncertain benefit–but not potential harms

12/12/2017

Gene therapy and hemophilia: Washington Post wisely tells readers ‘the study has some limitations’

11/14/2017

‘Regular painkillers work as well as opioids for fractures,’ but is this new information?

10/24/2017

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

8/31/2017

Washington Post’s otherwise well-reported story on ecstasy for PTSD skirts evidence discussion

7/18/2017

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

7/6/2017

Washington Post deftly examines lack of evidence for a fuzzy area of psychiatry: animal therapy

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

HealthNewsReview.org @HealthNewsRevu·

Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/

Reply on Twitter 1506684595651035136 Retweet on Twitter 15066845956510351361 Like on Twitter 15066845956510351364 Twitter 1506684595651035136

HealthNewsReview.org @HealthNewsRevu·

Our editorial team was blessed to have Sharon as a contributor during our best years. As this obit states, she was “kind, patient, wise, thoughtful and generous.” Thank you, Sharon; now rest in peace. https://journalism.wisc.edu/news/in-memoriam-sharon-dunwoody-1947-2022/

Reply on Twitter 1490898576763125760 Retweet on Twitter 1490898576763125760 Like on Twitter 14908985767631257602 Twitter 1490898576763125760

HealthNewsReview.org @HealthNewsRevu·

We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/

Reply on Twitter 1481386325567852553 Retweet on Twitter 14813863255678525531 Like on Twitter 14813863255678525536 Twitter 1481386325567852553

Categories: Washington Post

One woman’s account of spinal cord stimulator skips realities of medical device safety in U.S.

FDA approves new marijuana-derived drug, but was the evidence solid? Washington Post doesn’t say

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

Washington Post story on hyperbaric therapy for head injuries notes uncertain benefit–but not potential harms

Gene therapy and hemophilia: Washington Post wisely tells readers ‘the study has some limitations’

‘Regular painkillers work as well as opioids for fractures,’ but is this new information?

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

Washington Post’s otherwise well-reported story on ecstasy for PTSD skirts evidence discussion

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

Washington Post deftly examines lack of evidence for a fuzzy area of psychiatry: animal therapy

Story Reviews

@HealthNewsRevu

Categories

Tags